DEPOMED COMPLETES ENROLLMENT FOR GABAPENTIN TRIAL
Depomed has completed enrollment for a Phase II clinical trial evaluating the safety and efficacy of its Gabapentin extended release tablets to treat patients with postherpetic neuralgia, a long-lasting pain condition associated with nerve damage from herpes zoster, or shingles, infection.
The randomized, double-blind, placebo-controlled trial is fully enrolled with 158 postherpetic neuralgia patients. The primary objective is to assess the efficacy of Gabapentin twice daily compared to placebo in reducing mean daily pain scores. In addition, the trial will evaluate other safety and efficacy parameters, including sleep interference, a common problem of patients in pain.